Experience
EsoBiotec Announces up to $1 Billion Acquisition by AstraZeneca
March 17, 2025
Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.
Related contacts
Related Practices & Industries
PetLab Co. Announces Majority Stake Sale to BC Partners
February 26, 2025
Cooley advised PetLab Co., a rapidly growing independent pet supplement brand headquartered in London, on its majority stake sale to BC Partners, a top international investment firm.
Related contacts
Related Practices & Industries
Tenable to Acquire Vulcan Cyber
January 29, 2025
Cooley advised Tenable Holdings (Nasdaq: TENB), the exposure management company exposing and closing the cybersecurity gaps that erode business value, on its definitive agreement to acquire Vulcan Cyber, an innovator in exposure management, for $150 million in enterprise value.
Related contacts
Related Practices & Industries
Freshworks Agrees to Acquire Device42
May 3, 2024
Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.
Related contacts
Related Practices & Industries
MadCap Software Acquires Xyleme
January 11, 2024
Cooley advised MadCap Software, a multichannel content authoring, management and publishing solutions provider, on its acquisition of Xyleme, which offers intelligent content management for the development, control, delivery, and syndication of vital proprietary learning and development content across the enterprise.
Related contacts
Related Practices & Industries
Related news and events
Admissions and credentials
England and Wales
Memberships and affiliations
National Employment Lawyers Association